This paper describes a new method for enhancing the interaction of liposomes with cells. A novel class of cationic poly(ethyleneglycol) (PEG)-lipid (CPL) conjugates have been characterized for their ability to insert into pre-formed vesicles and enhance in vitro cellular binding and uptake of neutral and sterically-stabilized liposomes. The CPLs, which consist of a distearoylphosphatidylethanolamine (DSPE) anchor, a fluorescent dansyl moiety, a heterobifunctional PEG polymer (M r 3400), and a cationic headgroup composed of lysine derivatives, have been described previously [Bioconjug. Chem. 11 (2000) 433]. Five separate CPL, possessing 1^4 positive charges in the headgroup (referred to as CPL 1^C PL 4 , respectively), were incubated (as micellar solutions) in the presence of neutral or sterically-stabilized cationic large unilamellar vesicles (LUVs), and were found to insert into the external leaflet of the LUVs in a manner dependent on temperature, time, CPL/lipid ratio, and LUV composition. For CPL/lipid molar ratios 9 0.1, optimal insertion levels of approximately 70% of initial CPL were obtained following 3 h at 60³C. The insertion of CPL resulted in aggregation of the LUVs, as assessed by fluorescence microscopy, which could be prevented by the presence of 40 mM Ca 2 . The effect of CPL-insertion on the binding of LUVs to cells was examined by fluorescence microscopy and quantified by measuring the ratio of rhodamine fluorescence to protein concentration. Neither control LUVs or LUVs containing CPL 2 displayed significant uptake by BHK cells. However, a 3-fold increase in binding was observed for LUVs possessing CPL 3 , while for CPL 4 -LUVs values as high as 10-fold were achieved. Interestingly, the increase in lipid uptake did not correlate with total surface charge, but rather with increased positive charge density localized at the CPL distal headgroups. These results suggest that incorporation of CPLs into existing liposomal drug delivery systems may lead to significant improvements in intracellular delivery of therapeutic agents. ß 2001 Elsevier Science B.V. All rights reserved.
Introduction
Liposomes have long been recognized for their potential as in vivo drug carriers. For many conventional drugs, such as anticancer agents and antibiotics, a number of liposomal formulations have been developed which exhibit pharmacological utility [16 ] . Over the past decade, it has also become clear that liposomal systems possessing cationic lipids are highly e¡ective transfection agents in vitro [7, 8] . The addition of cationic liposomes to plasmid DNA gives rise to large complexes (commonly known as lipoplexes) that possess excellent transfection properties in vitro, but which are ine¡ective in vivo due to their rapid clearance from the circulation by the lung and other ¢rst-pass organs. The need for a non-viral lipid-based system capable of systemic delivery of genes to cells led to the recent development of stabilized plasmid-lipid particles (SPLP) [9] . These particles are small (V70 nm), contain a single copy of a plasmid vector, possess long-circulation properties resulting from a surface coating of poly(ethyleneglycol) (PEG), and protect DNA from degradation by serum nucleases. Current versions of SPLP exhibit low transfection potency, however, due to low levels of accumulation into target cells [10] .
In order to optimize the intracellular delivery of drugs (conventional or genetic) to cells, methods are required for increasing the uptake of liposomes into cells. Inclusion of speci¢c targeting information on the liposome surface, such as antibody-[11^13], vitamin-[14^18], oligopeptide- [19, 20] , or oligosaccharide- [20] constructs speci¢c for a particular membrane protein or receptor, have had limited success in achieving this goal in vivo, despite promising in vitro results. While speci¢c targeting of liposomes to tissues is a desirable objective, non-speci¢c targeting may also provide signi¢cant improvements in the effectiveness of liposomal carriers. For example, intracellular delivery of relatively speci¢c and non-toxic genetic drugs (antisense oligonucleotides and plasmids for gene therapy) could be expected to enhance therapeutic e¤cacy. In this paper, we describe a nonspeci¢c targeting approach that involves increasing the electrostatic attraction between liposomes and cells by incorporation of positively-charged lipid molecules into preformed vesicles. The positively charged lipid molecules are novel structures wherein a cationic headgroup (containing between 1 and 4 positive charges) is separated from the phospholipid anchor (and thus the vesicle surface) by a £exible, hydrophilic polymer, in this case PEG. These cationic PEG-lipid (or CPL) conjugates are labeled with a dansyl group, which allows rapid and accurate quanti¢cation using £uorescence techniques. The presence of CPLs in LUVs results in dramatic increases in the binding and uptake of vesicles by BHK cells in vitro.
We demonstrate the methodology for both cationic and neutral vesicles, with an emphasis on the former, as the cationic lipids present in lipoplex systems appear to play a direct role in stimulating uptake [21] and endosomal release [22] in cells. Neutral systems are also of interest as they comprise most conventional delivery systems.
The approach described herein has been developed and optimized within an in vitro context. Further development of CPL-carriers, or application of the post-insertion methodology to other targeted PEGlipids, may lead to in vivo applications ranging from enhanced delivery of conventional drugs to gene therapy.
Materials and methods

Materials
1,2-dioleoyl-phosphatidylcholine (DOPC), 1,2-dioleoyl-phosphatidylethanolamine (DOPE), and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(Lissamine Rhodamine B Sulfonyl) (rhodamine-PE) were obtained from Avanti Polar Lipids. Cholesterol, Octyl-glucopyranoside (OGP), and HEPES were obtained from Sigma Chemical Co. DODAC and PEGCerC 20 , PEGCerC 14 , and PEGCerC 8 were generous gifts from Inex Pharmaceuticals Corp. Slide-ALyzer dialysis membrane cassettes were obtained from Pierce.
Design and synthesis of cationic PEG lipids
The details of the design and synthesis of the CPLs has been previously described [23] . The dansylated cationic PEG-lipid conjugates (CPLs), illustrated in Fig. 1 , all have the same basic architecture, and consist of four moieties, conjugated in the following order: (i) a glycerolipid anchor (distearoylphosphatidylethanolamine (DSPE)), (ii) a lysine spacer containing a dansyl-label on the O-amino group, (iii) a PEG 3400 chain, at the distal end of which is covalently attached (iv) a positively charged headgroup made of linked lysine residues. By modifying the headgroup region, CPL were synthesized containing one, two, three, and four positive charges, with two varieties of the latter. As nearly all of the studies described in this paper involved the DSPE-CPL, the nomenclature speci¢es the charge of the headgroup as given in Fig. 1 (e.g., CPL 4a ).
Preparation of vesicles
Vesicles containing DOPE (or DOPC), the cationic lipid DODAC and the stabilizing lipid PEGCerC 20 were formed using a detergent dialysis method [9] . The lipids were co-dissolved in chloroform in the appropriate ratios, following which the chloroform was removed under a stream of nitrogen and placed under high vacuum for 2 h. An aliquot of the nonionic detergent octylglucopyranoside (OGP) (1 M in water) was then added to the dry lipid ¢lm, which was incubated for 10^20 min at 60³C with frequent Fig. 1 . Chemical structures of the DSPE-CPLs. Each CPL consists of a DSPE anchor, a dansylated lysine spacer, the PEG 3400 spacer chain, and a cationic headgroup (R) consisting of an amino group (CPL 1 ), a lysine residue (CPL 2 ), or linked lysine derivatives (CPL 3 , CPL 4a , CPL 4b ). The number of the CPL refers to the number of positive charges in the headgroup at physiological pH (where each amino group will be protonated).
vortexing. This was followed by addition of 20 mM HEPES, 150 mM NaCl (pH 7.5), with further warming and vortexing until all the lipid was dispersed and a clear solution was obtained. For 20 mg of lipid, 0.125 ml of OGP and 1 ml of HBS were used. The lipid-detergent solutions (1^2 ml) were then transferred to Slide-A-Lyzer dialysis membranes (3 ml volume) and exhaustively dialyzed at room temperature against HBS over a period of 48 h. In general, a total volume of 8^10 l of HBS was used (4^5 changes of 2 l) for sample volumes of 18 ml. Vesicles of DOPC and DOPC/Chol (55:45) were prepared by extrusion as previously described [24, 25] .
Insertion of CPL into preformed vesicles
The CPL were stored as micellar solutions in HBS or methanol. The CPL and the vesicles were combined to give the desired molar ratio (up to 11.6 mol% CPL relative to vesicle lipid), and incubated for a given time at the desired temperature. For most insertions, the standard conditions involved a 3 h incubation at 60³C. Following insertion, the samples were quickly cooled on ice to room temperature, and the CPL-LUV was separated from free CPL by passage down a column (1.5U15 cm) of Sepharose CL-4B equilibrated in HBS.
The insertion levels of CPL were measured by £uorescence. In all cases, the vesicles contained either 0.25 mol% or 0.5 mol% rhodamine-PE, and the CPL contained a dansyl group. After combining the CPL and lipids, a 15-Wl aliquot (initial fraction) was set aside for analysis. The amount of CPL inserted into the vesicles could then be quanti¢ed by measuring the initial dansyl/rhodamine (D/R) £uorescence ratio, and the D/R ratio of the isolated CPL-LUVs. For the rhodamine assay, the excitation wavelength was 560 nm, and the emission wavelength was 590 nm. For the dansyl assay, the excitation wavelength was 340 nm, and the emission wavelength was 510 nm. In general, the excitation and emission slit widths were 10 and 20 nm, respectively. The assay was performed as follows: to an aliquot of the initial sample (2^3 Wl) or the CPL-LUV (20^40 Wl) was added 30 Wl of 10% Triton X-100 followed by 2 ml of HBS. The £uores-cence levels of both the dansyl and rhodamine labels were read consecutively using a wavelength program as per the above parameters with an emission ¢lter of 430 nm. The %-insertion was calculated as follows:
Measurement of lipid concentrations
Lipid concentrations of LUVs were measured using the standard phosphate assay [26] . Following CPL insertion, lipid concentrations were estimated for cell binding studies from the rhodamine £uores-cence.
Preparation of lipid samples for high-performance liquid chromatography (HPLC) analysis
Prior to analysis by HPLC, lipids were extracted from the aqueous phase using a Bligh^Dyer procedure [27] . The organic phase was removed under a stream of N 2 gas, followed by 1 h under high vacuum. Samples were analyzed by HPLC at Northern Lipids, Vancouver, BC, Canada. (4) 3.4% CPL 4b . Incubations were performed for 1, 2, 4, and 6 h at 4³C and 37³C, the former giving an estimate of cell binding, and the latter of binding and uptake. By taking the di¡erence of the two values, an estimate of lipid uptake at 37³C was obtained. For each timepoint, the cells were washed twice with PBS and then lysed with 600 Wl of phosphate bu¡er (pH 8.0) containing 0.1% Triton X-100 followed by lipid and protein assays. Lipid concentrations were measured using rhodamine £uorescence, while protein was determined using the BCA assay kit obtained from Pierce. Where indicated, £uorescence micrographs were taken on an Axiovert 100 Zeiss £uores-cence microscope (Carl Zeiss Jena) using a rhodamine ¢lter from Omega Opticals (Brattleboro, VT) with the following speci¢cations: V ex = 560 þ 20 nm, LP = 600 nm, and DC = 590 nm.
Results
Development of insertion protocol
The transfer of PEG-lipid monomers from micelles to bilayers via the aqueous phase is a well-known phenomenon [20,28^30] . For example, MPEG 1900 -DSPE was found to insert into vesicles composed of PC/cholesterol/PG to levels as high as 3 mol% [30] . As the DSPE-CPLs are structurally similar and form micellar solutions, we anticipated that incubation of CPL solutions with vesicles would result in incorporation of some CPL in the external vesicle monolayer. The sections below describe the optimization of several variables that a¡ect the insertion process.
CPL insertion
The insertion of CPL 4b into neutral 100 nm vesicles composed of DOPC is illustrated in Fig.  2A ; experimental details are given in the ¢gure legend. The co-elution of the dansyl and rhodamine labels on a Sepharose CL-4B column demonstrates incorporation of the CPL in the LUVs. In this case, 84% of the CPL was incorporated into the LUVs, corresponding to a ¢nal insertion of 2.9 mol%, and thus only a trace of free CPL is observed trailing the CPL-LUV fractions. This is more clearly seen in Fig.  2B , where CPL 4b has been inserted into more complex positively charged vesicles composed of DOPE/ DODAC/PEGCerC 20 (84:6:10). Here, the co-elution of the two £uorescent labels at approx. 9 ml demonstrates 70% insertion of the CPL into the vesicles, corresponding to a ¢nal CPL concentration of 4.9 mol%. The free CPL micelles elute in a broad peak centered at 16 ml, which is separate from the vesicle peak, allowing for easy isolation of the CPL-LUV. Once inserted, the CPL 4b is retained and does not exchange out of the vesicles. The CPL-LUV fraction from Fig. 2B was re-eluted on the column of Sepharose CL-4B. As shown in Fig. 2C , all of the CPL remains with the LUVs. DOPC LUVs (2.5 Wmol lipid) were incubated with 0.085 Wmol CPL 4b (total volume 240 Wl) at 60³C for 3 h, following which the sample was applied to a column of Sepharose CL-4B equilibrated in HEPES-bu¡ered saline. One-ml fractions were collected and assayed for dansyl-labeled CPL (8) and rhodamine-PE (E) as described. (B) Insertion of CPL 4b into LUVs (100 nm) composed of DOPE/DODAC/PEGCerC 20 (84:6:10). LUVs (5 Wmol lipid) were incubated with 0.355 Wmol CPL 4b (total volume 519 Wl) at 60³C for 3 h, following which the sample was applied to a Sepharose CL-4B column equilibrated in HEPES-bu¡ered saline. One-ml fractions were collected and assayed for dansyl-labeled CPL (8) and rhodamine-PE (E) as described. The elution of free CPL (O) is also shown, demonstrating a straightforward method for isolation of the CPL-LUV. (C) Retention of CPL 4b in LUVs (100 nm) composed of DOPE/DODAC/PEGCerC 20 (84:6:10). The main LUV fraction from B was re-applied to a column of Sepharose CL-4B equilibrated in HEPES-bu¡ered saline. One-ml fractions were collected and assayed for dansyl-labeled CPL (8) and rhodamine-PE (F) as described.
PEGCerC 20 (84:6:10) at room temperature (25³C), 40³C, and 60³C, with aliquots withdrawn at 1, 3, and 6 h. The highest insertion levels were achieved at 60³C, which was therefore used in subsequent insertions. Although slightly higher insertion was obtained at 6 h, we chose 3 h to minimize potential sample degradation.
Aside from time and temperature, the parameter that will have the greatest in£uence on ¢nal CPL insertion levels is the initial CPL/lipid ratio. Assuming about 70% insertion, a series of incubations were performed with CPL/lipid ratios varying between 0.011 to 0.14, with the aim to achieve CPLLUVs containing 1, 2, 4, 6, 8, and 12 mol% CPL. These results are shown in Fig. 4A , where it is seen that the insertion level remains close to 70% up to an initial CPL/lipid ratio of 0.095, above which it drops to 50% for CPL/lipid = 0.14. Similar results were obtained for other vesicle systems, including DOPE/DODAC/PEGCerC 14 and DOPE/DODAC/ PEGCerC 8 (Fig. 4B) . In general, the insertion levels obtained with DODAC-containing samples fell in the range of 65^82% for initial CPL/lipid 6 0.1. The insertion levels tend to be higher at lower CPL/lipid ratios (Fig. 4B) .
E¡ect of lipid composition on insertion
In order to see whether the insertion levels were reduced in the absence of cationic lipid, several experiments were performed on neutral vesicles containing DOPC. The compositions examined were: (A) DOPC, (B) DOPC/Chol, (C) DOPC/PEGCerC 20 , and (D) DOPC/Chol/PEGCerC 20 . The results, shown in Fig. 5 , reveal signi¢cant levels of incorporation of both CPLs, albeit lower for CPL 4a (45^65%) than for CPL 4b (70^84%). The di¡erential behavior observed for these two lipids is probably a re£ection of the higher initial CPL/lipid ratio of the former. Nevertheless, comparison of the CPL 4a neutral lipid results with similar studies involving DOPE/DODAC/ PEGCerC 20 reveal signi¢cantly reduced insertion in the neutral LUVs. This may be due to reduced attraction between the negatively-charged DSPE anchor and the membrane surface. Regardless, the results demonstrate that signi¢cant insertion can be achieved for both neutral and positive vesicles.
A large number of insertions have been performed using other CPLs in addition to the CPL 4b and Fig. 3 . E¡ect of time and temperature on the insertion of CPL 4a into DOPE/DODAC/PEGCerC 20 LUVs. Insertions were performed at 60³C (R), 40³C (F), and 25³C (8) 
withdrawn and cooled on ice to halt insertion of CPL. The samples were passed down a Sepharose CL-4B column to remove excess CPL, and assayed for CPL insertion. Although there are some composition-dependent effects, in general we observe between 60^80% insertion for initial CPL/lipid ratios 6 0.1, with higher insertion observed at lower CPL/lipid ratios. Some minor trends are worth noting. The quantity of PEG-Cer present in the LUV a¡ects the ¢nal insertion levels. As the PEGCerC 20 content was increased from 4 to 10 mol%, the insertion level of CPL 4b fell from 71% to 62% (not shown).
E¡ect of CPL insertion on LUV lipid
composition The insertion of up to 7 mol% CPL into the external lea£et of an LUV might be expected to have some e¡ect on vesicle structure or composition. Of special concern was the possibility that incorporation of CPL might lead to expulsion of some PEGCerC 20 , which exchanges out of eggPC vesicles with a halflife for dissociation s 13 days [9] . This was examined by measuring the lipid composition of DOPE/DO-DAC/PEGCerC 20 LUVs by HPLC before and after the insertion of CPL 4b . As shown in Table 1 , the insertion of 3.5 and 6 mol% CPL 4b had no signi¢cant e¡ect on lipid composition, other than a small decrease in PEGCerC 20 content (from 8.3 to 7.5 mol%, relative to total lipid). It should be noted that the presence of 40 mM Ca 2 , which prevents or reverses vesicle aggregation (see Section 3.1.5), had no e¡ect on CPL insertion levels ( Table 2) or vesicle composition (Table 1) .
E¡ect of CPL insertion on vesicle aggregation
When examined under the £uorescence microscope, DOPE/DODAC/PEGCerC 20 LUVs labeled with 0.5 mol% rhodamine-PE exhibit a di¡use red background £uorescence. Following insertion of CPL 4b , large aggregates can be observed (data not shown). This aggregation can be reversed by the addition of 40 mM Ca 2 , following which a di¡use red £uorescence is again observed with no aggregates. The presence of calcium prevents the formation of aggregates. Interestingly, neither the CPL insertion levels (Table 2) , the composition of the CPL-LUVs (Table 1) , nor the diameters of the CPL-LUVs (Table 3) are altered by the presence of calcium. Quasi-elastic light scattering (QELS) was used to examine the e¡ect of CPL insertion on particle diameter (Table 3 ). In general, the insertion of CPL led to a small increase in vesicle diameter, usually on the order of 15 nm. Thus, the diameter þ S.D. of DOPE/ DODAC/PEG-Cer-C 20 vesicles were found to increase from 70 þ 22 nm to 87 þ 24 nm upon insertion of 6 mol% CPL 4b . Essentially identical results were obtained in the presence of 40 mM Ca 2 . That the aggregation observed by £uorescence microscopy was not manifest suggests that the aggregates were too large to be measured by QELS. The small observed size increase may result from the presence of the longer CPL PEG chains [30] , which may be expected to increase the particle radius. The size increase upon insertion of CPL is una¡ected by the quantity of CPL inserted or by the quantity of DODAC present in the vesicles. Identical size increases were observed for CPL concentrations ranging between 1.8 and 7.0 mol% (not shown). Furthermore, increasing the DODAC content from 6% to 18% had little e¡ect on CPL insertion or on the size increase. In all cases, samples remained optically clear, and there was no evidence of precipitation.
In vitro uptake of CPL-vesicles
As described in Section 2, estimates were obtained for the uptake of various CPL-LUVs on BHK cells incubated on PBS/CMG. The data, shown in Fig. 6 , reveals that the presence of positive charge on the CPLs can lead to signi¢cant enhancement in uptake by BHK cells. LUVs composed of DOPE/DODAC/ PEGCerC 20 (and thus exhibiting a net positive charge) showed little uptake on the BHK cells. LUVs containing 5.6 mol% of CPL 2 showed similar low uptake values. Uptake was only slightly increased by the presence of 5.7 mol% of CPL 3 . However, a signi¢cant increase in uptake (about 10-fold at 6 h) was realized for CPL 4b present at only 3.4 mol%. These results mirror our earlier studies in which CPL 4b -containing LUVs of DSPE/Chol/ Rho-PE exhibited 50-fold increased binding and uptake on BHK cells [23] .
The dramatic e¡ect of CPL insertion on LUV binding to BHK cells is most clearly visualized using £uorescence microscopy (Fig. 7) . In the absence of CPL, vesicles composed of DOPE/DODAC/ PEGCerC 20 and containing a trace of rhodamine-PE exhibit little binding to cells (Fig. 7A) . Incorporation of 3 mol% CPL 4b leads to high levels of vesicle binding and uptake (Fig. 7B) . Although much of the lipid appears to be binding to the cell surface, some small punctate structures can be seen, indicating that (8), (2) 5.6% CPL 2 (E), (3) 5.7% CPL 3 (R), and (4) 3.4% CPL 4b (b). Incubations were performed at 4³C and 37³C, the former giving an estimate of cell binding, and the latter of binding and uptake. By taking the di¡erence of the two values, an estimate of lipid uptake at 37³C was obtained. uptake of vesicles is also occurring, as shown in Fig.  6 . An important point to note is that the cells (Fig.  7C,D) appear healthy following incubation in the presence of the CPL-LUVs. Similar results to those described above have been observed for BHK cells grown in the presence of 10% FBS, for binding studies involving DOPE/DODAC/ PEGCerC 20 /Rho-PE LUVs containing both 3.2 mol% CPL 4b and remote-loaded doxorubicin (drugto-lipid ratio = 0.12 mol:mol) (D.B. Fenske, A.L. Ng, unpublished results). In addition, 10% FBS was also present in our earlier studies that demonstrated enhanced binding of CPL 4b /DSPE/Chol/Rho-PE LUVs on BHK cells [23] .
Discussion
One of the major remaining hurdles in liposomal drug delivery is the problem of how to ensure that the contents of a carrier system are taken up and utilized by a speci¢c target cell. Cellular uptake of liposomes involves adsorption or binding at the cell surface, followed by endocytosis. Thus factors which interfere with cellular binding will lead to low levels of intracellular delivery. This is of particular importance for`stealth' or long-circulating liposomes that are coated with a surface layer of a hydrophilic polymer such as PEG. The very characteristic of the PEG coating which imparts long-circulation lifetimes^the formation of a steric barrier that prevents interaction with serum proteins will also minimize interactions with cells. On the other hand, factors that enhance surface binding may be expected to lead to increased cellular uptake. One approach involves attaching molecules speci¢c for membrane receptors to liposomal surfaces. Possible candidates include oligopeptides [19, 20] , oligosaccharides [20] , folate [14^16,18], ribo£avin [17] , or antibodies [11^13]. An alternate approach is to modify the charge characteristics of the liposome. It is well known that inclusion of either negative [21,31^33] or positive [21] charges in liposomes can lead to enhanced cellular uptake in vitro. Cationic DNA^lipid complexes, which are positively charged, e¤cient in vitro transfection agents [7, 8, 12, 34, 35] , are taken up via endocytosis. This paper describes a new approach for enhancing the interaction of liposomes with cells, a necessary step in the eventual development of non-viral systems capable of intracellular delivery. The approach involves the insertion of novel cationic PEG-lipids into pre-formed liposomes, leading to a cationic vesicle in which the positive charge involved in cell interaction is located some distance away from the vesicle surface. The process is illustrated in Fig. 8 for the insertion of a CPL 4 into sterically-stabilized LUVs composed of DOPE, the cationic lipid DO-DAC, and PEGCerC 20 . This lipid composition was chosen for study for two reasons: ¢rst, it allows for e¤cient entrapment of plasmid DNA within small vesicular particles (SPLP) by virtue of the presence of positively charged DODAC [9] , and thus has potential as a systemic gene delivery system (see below). Secondly, this composition is representative of the many sterically-stabilized drug delivery systems which contain PEG-lipids. Unfortunately, both SPLPs and the vesicles examined in the present study exhibit low levels of uptake in vitro. Insertion of CPLs leads to localization of positive charge above the surface PEG layer, thereby allowing electrostatic interactions between the CPLs and cell surfaces. For in vitro studies, this should lead to increased cellular interactions for both conventional-and PEG-containing liposomes.
One might question the advantages of inserting CPLs into pre-formed vesicles rather than simply including the CPL as a lipid component during vesicle formation. While the latter approach would work with conventional vesicles, problems would arise in formulation processes where plasmid DNA was present, such as in the formation of SPLP. Encapsulation of DNA within SPLP requires interactions between the cationic lipid DODAC and negatively charged plasmid: if present, CPL would doubtless interfere with this process, either by interacting with plasmid (and thereby reducing the CPL quantity present on the vesicle surface), or by altering the optimal charge ratio for DNA encapsulation. The post-insertion protocol has the advantage of being completely general to any liposomal system.
The approach described in this paper for inserting CPLs into pre-formed vesicles builds on several recent related studies. The transfer of PEG-lipid conjugates from micellar phase to vesicles has been described for MPEG 1900 -DSPE [30] , PEG 5000 -DPPE and PEG 5000 -DSPE [36] , and for oligopeptide PEG-DSPE and oligosaccharide PEG-DSPE conjugates [20] . In these studies, between 1 and 3 mol% of conjugate (relative to total lipid) was incorporated into the target membranes. These values are signi¢cantly lower than the maximum insertion levels we report for the CPLs (up to 7 mol%). In addition, the oligopeptide/oligosaccharide PEG-DSPE conjugates could be inserted to 1.2 mol% into vesicles containing 3 mol% MPEG-DSPE, demonstrating the potential for using this approach with long-circulating lipo- somes. In our systems, high insertion levels (up to 7 mol%) could be achieved for vesicles containing V7 mol% PEGCerC 20 . Although PEG-Cers will exchange from vesicles both in vitro [9] and during circulation [37, 38] , only a small portion of the PEGCerC 20 appears to be lost during CPL insertion (Table 1) .
A recent study by Zalipsky and co-workers [14] reported on the incorporation of folic acid PEG-DSPE conjugates into vesicles, and demonstrated enhanced binding to cells expressing the folate receptor. The best binding was observed for vesicles containing only the folate PEG-DSPE conjugate. The presence of additional mPEG-DSPE greatly reduced binding, particularly when the length of the PEG in the two molecules was identical. Enhanced binding was only observed for vesicles containing folate-PEG 3350 -DSPE and mPEG 2000 -DSPE. This mirrors our system, where the M r s of the PEG in the CPL and PEG-Cers are 3400 and 2000, respectively, and suggests we should be able to modulate cell binding by varying the lengths of the two PEG spacers (see below).
As shown in Fig. 6 , cationic LUVs composed of DOPE/DODAC/PEGCerC 20 exhibit little uptake when incubated on BHK cells. Although positively charged vesicles exhibit enhanced binding to some cell lines, this can be attenuated by the presence of PEG on the liposome surface [21] . Clearly, for these systems, the presence of 6 mol% of positively charged DODAC leads to only low uptake levels after 6 h. Incorporation of 5.6 mol% of CPL 2 has little e¡ect on uptake, which was only slightly improved in the presence of 5.7 mol% CPL 3 . The best results were obtained with the CPL 4b (at 3.4 mol%), which possessed four positive charges. At 6 h incubation, a 10-fold increase in uptake was observed relative to the control vesicles. Several points can be surmised from these data. The ¢rst is that the presence of positively charged groups located some distance from the LUV surface can lead to signi¢cant increases in cellular uptake. In this case, the positive charges of the CPL (PEG M r = 3400) are located above the surface coating of PEG (M r = 2000), and thus are available for interactions with cells. However, it is not total charge alone that plays a role in enhanced cell binding. The quantity of positive charge present for the CPL 2 and CPL 4b samples is approximately equal, and yet the former shows little uptake compared to the latter. The CPL 3 sample has a greater total positive charge than the CPL 4b sample, and yet exhibits only a third of the uptake. It would appear that localization of a su¤cient positive charge density at the distal end of the CPL molecule is an important parameter in ensuring interaction with cells. At least four charges seem to be required for e¤cient cell binding to occur.
The results of this paper demonstrate that the interaction of LUVs with cells in vitro can be signi¢-cantly enhanced by increasing the positive charge present on the LUV surface by post-insertion of CPL. The additional positive charge must be physically distant from the surface to be available for interactions with cells, particularly when working with polymer-coated vesicles that are designed for minimal interactions with serum proteins and macrophages. This naturally leads to questions concerning the design of next generation liposomal systems capable of systemic drug or gene delivery following i.v. administration. First, it should be noted that the CPL systems described here are unlikely to be of direct utility as systemic delivery vectors. This is because the CPL employed contains a PEG 3400 linker, and thus the cationic groups at the end of the PEG will extend beyond the PEG 2000`c loud' provided by the PEG-Cer components of the LUVs. Charged liposomal systems are rapidly cleared from the circulation following i.v. administration, and it would therefore be expected that the systems employed here would not exhibit the long circulation lifetimes that lead to accumulation at disease sites such as tumors. Strategies that could overcome this di¤culty include the possibility of inserting CPL containing a shorter PEG linker, such as PEG 1000 . The positive charge should then be shielded by the PEG 2000 of the PEG-Cer, leading to longer circulation lifetimes. If necessary, a greater degree of shielding could be achieved by insertion of the shorter-chain CPL into systems containing PEG-Cer molecules prepared using PEG 5000 . A remaining problem concerns the need to achieve exposure of the CPL after arrival at the tumor site to stimulate uptake into cells. As we have noted elsewhere [9, 36, 37] , the PEG-Cer component of liposomal systems can be designed to dissociate over a time determined by the length of the acyl chain contained in the ceramide anchor. If the PEG-Cer is designed to dissociate slowly, a situation can be envisioned where LUV that have accumulated at a disease site such as a tumor will lose the PEG shield, thus exposing the CPL which stimulate uptake. An alternative possibility is to post-insert lipids containing speci¢c targeting ligands, that do not stimulate clearance, at the end of the PEG linker. Optimizing these systems for in vivo use will thus involve varying the chain length of the PEG polymers of both CPL and PEGCer, and of the fatty acyl moieties which determine PEGCer exchange rates.
In summary, the results presented here demonstrate the insertion of a new class of cationic ligands into preformed liposomal systems, leading to increased uptake into cells. The approach should be generally applicable to liposomes containing small molecule drugs (e.g., anticancer drugs) as well as liposomes containing macromolecular drugs, such as plasmids containing genes coding for therapeutic proteins. Current studies are focused on applying this approach to a new class of lipid-based DNA carrier systems known as stabilized plasmid^lipid particles (SPLPs) [9] .
